A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs NC-318 (Primary)
- Indications Breast cancer; Carcinoma; Colorectal cancer; Endometrial cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors NextCure
- 11 Nov 2019 Planned number of patients changed from 110 to 143.
- 09 Nov 2019 According to an NextCure media release, Phase II portion of this trial has been initiated and company expects to report initial data from the Phase II portion by the end of 2020.
- 09 Nov 2019 According to an NextCure media release, updated results from Phase I portion of this trial were presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).